Imagine visiting your doctor in your 30s and being told you might need a cholesterol-lowering pill—not because you feel sick today, but because of what could happen decades from now. That future-focused conversation is becoming more common, thanks to updated heart health guidelines that recommend statins for more Americans than ever before.
A new study from the University of Pittsburgh finds that 56.6% of U.S. adults ages 30 to 79—about 87.5 million people—are now eligible for statins to help prevent heart attacks and strokes. That is up from a smaller group under previous guidelines, meaning an additional 21.5 million Americans are now recommended for the medication.
The shift comes from new rules released in March 2026 by the American Heart Association, the American College of Cardiology, and other medical groups. What changed? Doctors are now encouraged to look at a person's risk over 30 years, not just the next 10. The age range for eligibility also widened from 40–75 years old to 30–79 years old.
"The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients," said Dr. Timothy S. Anderson, a primary care physician and researcher at the University of Pittsburgh who helped write the new guidelines.
The researchers analyzed health data from about 4,366 people across the country, representing roughly 154.5 million American adults without existing heart disease. They found that age matters a lot when it comes to risk. Only 11.1% of people in their 30s are recommended for statins, but that number jumps to 85% for people in their 60s and 93.5% for those in their 70s.
Much of the growth in eligibility comes from people who look low-risk if you only check the next 10 years—but have a meaningful chance of heart problems over 30 years. Anderson said many younger patients ask why they cannot wait to start treatment, which he finds understandable. But for those who want to lower their odds of heart attack or stroke as much as possible, starting earlier may be worth considering.
The science behind this longer view comes from observational research, not gold-standard clinical trials, because waiting 30 years for trial results is impractical. Still, Anderson notes that the longer someone's cholesterol stays high, the higher their long-term risk tends to be.
"Ultimately, in this gray zone, patients should talk to doctors," Anderson said. "This is a preference-based decision that should take into account the potential for modest cardiovascular risk reduction alongside the potential for side effects and the burden of taking a daily pill."
The new guidelines give doctors and patients more information to work with—and more options to consider for protecting heart health over a lifetime.